WST · Q3 2025 Earnings

Bullish

West Pharmaceutical Services

Reported October 23, 2025

30-second summary

Revenue grew 7.7% YoY to $804.6M (organic +5.0%), beating the prior Q3 guide of $785–795M, with adjusted EPS of $1.96 crushing the $1.65–1.70 guide by $0.26–0.31. Management raised FY2025 EPS guidance by $0.41 at the midpoint to $7.06–7.11 and lifted organic growth to 3.75–4.0%, marking a second consecutive mid-year raise driven by HVP Components (+16.3% reported, +13.3% organic) and the Annex 1 contribution being bumped from 150bps to 200bps. The "transition year" framing is fully retired; the new posture is that destocking is "largely behind us" and growth drivers are sustainable.

Headline numbers

EPS

Q3 FY2025

$1.96

Revenue

Q3 FY2025

$0.80B

+7.7% YoY

Gross margin

Q3 FY2025

36.6%

Operating margin

Q3 FY2025

20.8%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$0.80B	+7.7%	$0.77B	+5.0%
EPS	$1.96	—	$1.84	+6.5%
Gross margin	36.6%	—	35.7%	+90bps
Operating margin	20.8%	—	20.1%	+70bps

Guidance

Company raised full-year FY2025 revenue and EPS guidance, lifting organic growth outlook and signaling confidence in sustained HVP demand; Q3 results beat both prior revenue and EPS guides, with Q4 forward guidance introduced.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q3 FY2025	$785M to $795M	$804.6M	+$9.6M to +$19.6M above guide	Beat
Adjusted-Diluted EPS	Q3 FY2025	$1.65 to $1.70	$1.96	+$0.26 to +$0.31 above guide	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	Q4 FY2025	$790M to $800M	—
Adjusted-Diluted EPS	Q4 FY2025	$1.81 to $1.86	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2025	$3.040B to $3.060B	$3.060B to $3.070B	+$0.010B at midpoint (from $3.050B to $3.065B)	Raised
Adjusted-Diluted EPS	FY2025	$6.65 to $6.85	$7.06 to $7.11	+$0.41 at midpoint (from $6.75 to $7.085)	Raised
Organic Revenue Growth	FY2025	3.0% to 3.75%	3.75% to 4.0%	+0.25% at midpoint (from 3.375% to 3.875%)	Raised

Reaffirmed unchanged this quarter: Capital Expenditures ($275M)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Proprietary Products	$0.648B	+7.7%
HVP Components	$0.39B	+16.3%
HVP Delivery Devices	$0.099B	-15.7%
Standard Products	$0.158B	+6.7%
Contract-Manufactured Products	$0.157B	+8.0%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Americas	$0.375B	+5.3%
Europe, Middle East, Africa	$0.361B	+9.4%
Asia Pacific	$0.068B	+13.1%
Organic Revenue Growth	5.0%	—
HVP Components Organic Growth	13.3%	—
Adjusted Operating Margin	21.1%	—
Operating Cash Flow (9M)	$503.7M	—
Free Cash Flow (9M)	$293.9M	—
Share Repurchases (9M)	$134.0M	—
Biologics Market Growth	11.0%	—
Pharma Market Growth	4.7%	—

Management tone

Q2 anchor → Q3 anchor: "Transition year retired, momentum building" → "Destocking is behind us, raise the guide again."

The Annex 1 contribution was quantitatively raised mid-year, not just qualitatively reaffirmed. Last quarter the contribution was disclosed at ~150bps for 2025; this quarter management stated they "anticipate Annex 1 and related HPP upgrades to deliver 200 basis points of growth this year, up from our previous expectation of 150 basis points" with 375 ongoing projects. A 50bps mid-year lift to a multi-year growth driver is the most consequential numerical change on the print and validates the HPP components strategy beyond a single strong quarter.

Destocking language shifted from "normalizing" to "largely behind us." Q2's framing was "we're optimistic that our businesses in these markets are turning back to more normal ordering patterns." This quarter management said outright: "We believe destocking is largely behind us, and demand will continue to improve for our key growth drivers." That is a definitive declaration after six quarters of sector-wide inventory-correction commentary, and it is the language change that justifies the organic growth raise.

GLP-1 disclosure went from emerging opportunity to quantified pillar. Two quarters ago GLP-1 was discussed as a growth contributor without specific revenue share; this quarter management explicitly split it: elastomers for GLP-1 at 9% of total company sales, GLP-1 contract manufacturing at 8% — combined 17% of revenue. Disclosing concentration this precisely signals management is comfortable having the number scrutinized, and frames the upcoming CGM contract roll-off ($40M headwind mid-2026) against a much larger GLP-1 base.

HVP Components growth is accelerating sequentially. Q3 organic growth of +13.3% built on continued sequential strengthening through the year, and management guided Q4 HVP Components growth to "low to mid-teens" — explicitly framing the momentum as continuing rather than peaking.

New Dublin drug-handling contribution was put on the table for 2026. Management quantified the Dublin liquid-handling buildout at "roughly $20 million in revenue for next year," with peak volumes pushed to 2027 and beyond. Adding a specific 2026 dollar contribution this far out — alongside flagging the $40M CGM headwind — represents an unusual willingness to frame next year's puts and takes from the Q3 print.

The forward posture is more confident than is typical for WST. Management's prepared comment that "our business momentum is steadily improving, and we expect this trend to continue" is forward-leaning relative to West's normally measured cadence, and is reinforced by two consecutive quarterly raises to both revenue and EPS guidance.

Recurring themes management leaned on this quarter:

GLP-1 market expansion and elastomer penetrationAnnex 1 HPP upgrades as multi-year tailwindHVP components margin expansion and mix improvementBiologics normalization and participation rate strengtheningManufacturing capacity resolution in GermanyContract manufacturing pivot toward higher-margin obesity/diabetes devices

Risks management surfaced:

End markets remain dynamic with potential range of outcomesGermany manufacturing site constraints ongoingCGM contract conclusion at end of Q2 2026 creating $40 million headwind$15-20 million tariff-related costs in 2025Uncertainty in 2026 planning despite current positive trends

Q&A highlights

Daniel Markowitz · Evercore ISI

Two-part question on high-value components headwinds/tailwinds for 2026 and GLP-1 elastomer growth sustainability. Asked if GLP-1 growth exceeds 50% and whether over 20% growth can be sustained.

Management confirmed strong GLP-1 growth trajectory driven by market expansion, vial volume increases, clinical trial participation, and geographic/generic expansion beyond just Novo/Lilly. Emphasized five global HVP manufacturing centers provide scale. Noted Annex 1 timing variability but high confidence in pipeline. Acknowledged law of large numbers will moderate GLP-1 growth rates but expects continued healthy growth. Identified potential FDA approval timing uncertainty as a minor headwind.

GLP-1 now represents ~9% of total revenues (up from mid-single-digit % in 2024)Five high-value product manufacturing plants globallyAnnex 1 market opportunity of 6 billion components with only a small fraction currently convertedStandard product margins 20-30% vs HVP margins 60%+

Patrick Donnelly · Citi

Follow-up on CDM contract exit impact and revenue backfill timing. Also asked about longer-term margin expansion opportunities including footprint optimization and operational efficiencies.

Management stated CDM Dublin facility exit mid-2026 has $40M headwind. Engaged with multiple customers to replace contract with higher-margin business. Noted transition period includes engineering fees to partially offset gap. Addressed footprint optimization as medium-to-longer term opportunity with potential to consolidate certain areas for greater efficiency. Not a 2026 priority but signals additional margin upside beyond near-term.

$40 million headwind from CDM contract exit mid-2026Future contract economics expected to be stronger than current agreementTransition-period engineering fees will partially offset revenue gapNew commercial operations expected end-2026 if straightforward process

Michael Ryskin · Bank of America

Asked about sustainability of HVP double-digit growth and specific moving pieces driving margin expansion (gross margin vs volume leverage vs cost actions).

Management highlighted sequential strengthening of HVP growth as order patterns normalize. Attributed momentum to biologics/biosimilars confidence, Annex 1 multi-year conversion algorithm, and bioprocessing indicators. For margins, emphasized mix benefit of HVP upgrade, factory efficiency gains from prior investments, and cost reduction opportunities. Guided to low-mid-teens HVP growth in Q4. Noted more challenging comps in back-half 2026.

Q4 HVP guidance of low to mid-teens growthBioprocessing space used as key indicator of near-to-midterm demandQ3 gross margin up 120 bps YoY despite incentive fee (up 300 bps on like-for-like basis)Margin expansion from both gross margin and below-line efficiency opportunities expected

Larry Solo · CVS Securities

Asked about whether improvement in gross margin is driven by mix shift within HVP toward higher-margin products like NovaPure, and if this dynamic continues.

Management confirmed mix improvement as key driver. Highlighted that despite incentive fee, gross margin up 120 bps YoY (300 bps on like-for-like). Attributed gains to: (1) fixed cost leverage from capacity investments, (2) higher ASP HVP products, (3) scrap/yield improvements, (4) raw material sourcing improvements, (5) production process streamlining. Characterized these as multi-year opportunities with runway ahead.

Gross margin up 120 bps YoY, 300 bps on adjusted basisIncremental margins "quite nice" from fixed cost leverageFocus areas: scrap reduction, yield improvement, raw material sourcing, production process optimizationMulti-year margin opportunity runway identified

Justin Bowers · Deutsche Bank

Two-part: (1) How Annex 1 updates are impacting customer decision-making and accelerating conversions, (2) Is the $20M Dublin liquid handling opportunity the peak or room for growth beyond 2026.

On Annex 1, management noted increased EU regulator engagement with customers is accelerating project interest. Confirmed still in early stages with only small fraction of 6B component market converted. On Dublin, clarified $20M is ramp-up stage in early phases, with peak volumes and revenues coming in 2027 and beyond as utilization increases. Not peak opportunity.

$20 million Dublin liquid handling is ramp-up stage, not peakPeak volumes/revenues expected 2027 and beyondIncreased EU regulatory discussions driving Annex 1 acceleration6 billion component market opportunity with only small fraction in commercial conversion

Answers to last quarter's watch list

HVP Components growth holding above 10% YoY in Q3. Resolved positively. HVP Components grew +16.3% reported / +13.3% organic in Q3, with Annex 1 contribution raised from 150bps to 200bps and project pipeline at 375. Status: Resolved positively

HVP Delivery Devices growth durability. HVP Delivery Devices reversed to -15.7% reported / -16.7% organic YoY in Q3, which management attributed primarily to the prior-year $19M one-time incentive fee comp. Management did break out GLP-1 contribution (elastomers 9% of sales, contract manufacturing 8% — 17% combined). Sequentially, the business was roughly flat as expected. Status: Continue monitoring

Standard Products returning to growth. Resolved positively. Standard Products grew +6.7% reported / +3.6% organic in Q3 — a meaningful acceleration on an organic basis and the strongest validation yet of the "destocking is behind us" narrative. Status: Resolved positively

Tariff impact reconciling to the $15–20M range. Management continues to expect $15–20M in tariff-related costs for 2025, and now expects to mitigate more than half within the year and fully mitigate the impact in 2026 based on the current tariff landscape. Status: Resolved positively

Capex trajectory commentary toward the 6–8% normal range. FY2025 capex reaffirmed at $275M; management explicitly stated they "feel comfortable that we're going to be back to the 6% to 8% of sales corridor for CapEx." Dublin drug-handling will add ~$20M of 2026 revenue, but no specific FY2026 capex figure was provided. Status: Continue monitoring

Annex 1 contribution tracking to the disclosed ~150bps for 2025. Resolved positively and then some. Annex 1 contribution lifted to 200bps from 150bps, 375 projects ongoing, and management flagged increased EU regulator engagement accelerating customer interest. 2026 quantification was not provided, but the project pipeline supports a multi-year contribution. Status: Resolved positively

What to watch into next quarter

Does HVP Delivery Devices stabilize? Sequential performance was roughly flat in Q3 as expected, but watch whether Q4 returns the segment to positive YoY growth as the prior-year incentive fee comp continues to roll through.

Q4 organic growth landing inside the 1.0%–2.3% guide. A print at or above the high end would suggest conservatism; below the low end would mean the FY raise was back-loaded into a Q3 that has now over-earned. Reported growth guide of 5.5%–6.8% is the more relevant comp given the prior-year incentive fee distortion.

First quantified FY2026 framing. Management explicitly said "2026 is coming into better focus" — watch for an Investor Day or initial FY2026 commentary that nets the $40M CGM headwind, the $20M Dublin contribution, and any 2026 Annex 1 quantification. Without it, the 2026 setup remains hand-waved.

Capex stepping toward the 6–8% normal range. A FY2026 capex disclosure consistent with that corridor would mark the FCF inflection management has telegraphed for two quarters.

HVP Components sustaining low-mid teens growth in Q4 (management guided), confirming Annex 1 / HPP upgrade demand is structural rather than pull-forward.

Gross margin holding above 36% with the incentive-fee headwind annualized. Q3's 36.6% (+120bps reported, ~300bps like-for-like) needs to durably exceed last year's Q4 print to validate the mix + operational efficiency narrative.

Sources

West Pharmaceutical Services Q3 2025 Earnings Release (SEC EDGAR): https://www.sec.gov/Archives/edgar/data/105770/000010577025000090/exh991q32025earningsrelease.htm
West Pharmaceutical Services Q3 2025 prepared commentary and Q&A (referenced for Annex 1 project count, GLP-1 revenue share, Dublin facility ramp, destocking language, gross margin bridge)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.